Annals of Medicine · 1990 · 11 citations · 25 references
MedicineBiochemistryOncologyCancer GeneticsMetabolomicsPharmacogenomics In OncologyBladder CancerCancer MetabolismCancer MetabolomicsCarcinogen MetabolismDrug Metabolism PolymorphismsMetabolic Pathway PolymorphismsMetabolic PolymorphismsMetabolism Enzyme PolymorphismsOxidative Stress In Cancer
The oxidative polymorphism of debrisoquine has been determined in 125 patients with bladder cancer and in 556 healthy control subjects; 96.6% of patients and 93.9% of controls with a metabolic ratio of debrisoquine less than 12.6 were classified as extensive metabolizers of debrisoquine (P = NS). The distribution of frequencies of metabolic ratio values tended to have lower values in the patients (P less than 0.05), reflecting a higher oxidative rate of debrisoquine in urothelioma patients that cannot be explained solely in terms of enzymatic induction by drugs, tobacco or alcohol. Patients with a high occupational risk for urothelioma had lower metabolic ratio values (P = 0.03). Our results suggest that oxidative polymorphism of debrisoquine might be related to the pathogenesis of bladder cancer.
25
Nonparametric Statistical Methods
Technometrics · 1999 · 6.2K citations
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
A. Mahgoub, L. G. Dring, Jeffrey R. Idle et al. · The Lancet · 1977 · 1.2K citations